Oslo and Toulouse Cancer Clusters Join Forces to Drive European Cancer Resear... ( OSLO TOULOUSE France and PARIS No...)

Oslo and Toulouse Cancer Clusters Join Forces to Drive European Cancer Research Forward

Date:11/13/2008

OSLO, TOULOUSE, France and PARIS, November 13 /PRNewswire/ -- Oslo Cancer Cluster today signed a groundbreaking strategic agreement with the Toulouse Canceropole and Cancer-Bio-Sante Cluster which will lead to an integrated effort to become the leading cancer centers in Europe for developing new cancer therapies. The signatories were Philippe Douste-Blazy, President of Canceropole Toulouse Association, former mayor of Toulouse and former French foreign minister, Jean-Pierre Saintouil, CEO of Toulouse Cancer-Bio-Sante Cluster and Bjarte Reve, CEO of Oslo Cancer Cluster NCE. It also contained an initial series of key initiatives to be implemented over the next two years, including a joint response to the next cancer calls of the EU -Innovative Medicines Initiative.

According to Bjarte Reve, the agreement stems from growing recognition that combined research and industry-based clusters focusing on a particular therapeutic area are the way forward: "Oslo and Toulouse are pioneers in this area. Through partnership between the life science industry, research institutions, university hospitals, government and the Norwegian Cancer Society, we have been able to rapidly develop the Oslo Cancer Cluster. Having developed links with like-minded centres in the US, such as MD Anderson, when we turned to Europe, Toulouse stood out as a potential partner. We are therefore delighted to have signed this agreement and to share our vision of ensuring that patients have access to the latest cancer diagnostics and therapeutics as quickly and cost-effectively as possible."

Philippe Douste-Blazy , initiator of the Toulouse project, congratulated the creators of this collaboration and stressed the similarities between Oslo and Toulouse: "This is especially evident in their ethical approach that cannot be categorized as a purely economic approach but instead places the patient at the heart of the concept."

Jean-Pierre Saintouil, also welcomed the agreement: "Our ex
'/>"/>

1

GOOD

Page: 1 2 3
Related biology technology :

1. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
2. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
3. Max Planck Institute of Biochemistry Uses MathWorks Tools in Its Quest to Cure Cancer : Institute Accelerates Reconstruction of Key Protein Complexes Using MATLAB and Parallel Computing Toolbox
4. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
5. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
6. Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems
7. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
8. Bradmer sponsors physician panel to raise awareness of brain cancer treatments
9. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
10. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
11. Data Presented at Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests

Post Your Comments:

Oslo and Toulouse Cancer Clusters Join Forces to Drive European Cancer Resear...( OSLO TOULOUSE France and PARIS No...)